Here’s what you should know.
Vizient awarded the designation because of the company’s D-Light C Photodynamic Diagnostic system. The system detects and manages non-muscle invasive bladder cancer.
Vizient’s designation defines products that “hospitals truly value.”
Debbie Archer, director of procurement and leader of Vizient’s Innovative Technology program said “Vizient’s member council agreed [diagnostic system] offers unique and incremental benefit over other products available on the market today, and recommended it for an Innovative Technology designation.
More articles on gastroenterology/endoscopy:
Exact Sciences, Takeda Pharmaceuticals & more — 6 GI company key notes
GI leader to know: Dr. Deborah Blalock of Blalock GI Care
How investors reacted to Valeant’s $2.1B sell off: 4 key insights
